Arrow Greentech Limited Overview
Arrow Greentech is a promoter-controlled, IP-led Indian specialty-materials micro-to-small-cap that operates two economically distinct engines under one roof. Its High-Tech Products segment — anti-counterfeit security films, threads, fibres, laminates and related intellectual-property income, largely sold to high-security paper mills and document/brand-protection customers, partly through a Netherlands subsidiary — generated roughly 82% of FY26 revenue and nearly all of the swing in earnings. Its Green Products segment, built on the Watersol® brand, makes the company India's largest manufacturer of cast polyvinyl-alcohol (PVA/PVOH) water-soluble films for agrochemical, detergent, construction-chemical, embroidery and healthcare packaging, plus bio-compostable films; it grew 52% in FY26 to INR 369 Mn. A third, still loss-making option is Avery Pharmaceuticals' mouth-dissolving strip platform. The business is effectively debt-free, carries ~INR 1,294 Mn of cash and investments, earns 30–40% EBITDA margins in strong quarters, and exhibits pronounced order-driven volatility.
Company's own description
In its FY26 Annual Report, management frames Arrow Greentech as an innovation-and-IP franchise — the Chairman's letter characterises innovation as the company's "identity" and describes patents as its deepest moat. The company describes itself as "India's largest manufacturer of water-soluble films, marketed under our Watersol® brand", with a widening basket of bio-compostable solutions, alongside a High-Tech and Security business that manufactures anti-counterfeit products, security elements and security films for document, brand and high-security applications [AR26]. Its investor materials enumerate five business lines: Water Soluble Films, Intellectual Property, Security Products, Avery Pharma, and Other (Watersol Capsules and BioPlast) [IP-Aug26].
Morningstar's business description (derived from filings) states that the operating segments are Green Products (Water Soluble Films, Bio-Compostable Products, other green products) and Hightech Products (Anti-Counterfeit Products, IPRs and other high-tech products), with the Hightech segment generating the majority of revenue [Morningstar].
Business model and revenue model
| Revenue stream | Nature | Segment | Approx. FY26 weight | Comment |
|---|---|---|---|---|
| Security films, threads, fibres, laminates, brand-protection elements | Product sales (B2B, order/tender-driven) | High-Tech | Majority of ~INR 1,636 Mn | Lumpy; customer-order timing and procurement cycles drive quarterly swings [AR26] |
| Patent out-licensing, know-how transfer, IP income | Licensing / royalty | High-Tech | — | Company states it monetises key patents through out-licensing and production of patented products [IP-May26] |
| Trading of raw materials for security products | Traded goods | High-Tech | — | "Purchase of stock in trade" was INR 339 Mn in both FY25 and FY26, indicating a material traded component [IP-May26]; company states it deals in supply of various raw materials [IP-Aug26] |
| Watersol® PVA water-soluble films | Product sales (B2B industrial) | Green | Majority of INR 369 Mn | Agrochemical, detergent unit-dose, embroidery, construction chemicals, laundry bags, mould release |
| Bio-compostable films (BioPlast) and Watersol Capsules | Product sales | Green | Small | Single-use plastic substitution |
| Mouth Dissolving Strips (MDS) — nutraceutical and Rx; CDMO | Product sales and contract development/manufacturing | Reported within group; Avery turnover INR 37.0 Mn in FY26 | ~2% | Loss-making subsidiary [AR26 AOC-1] |
The mix is therefore predominantly product sales, with a licensing/IP overlay that is disclosed qualitatively but not quantified separately in the documents reviewed. There is no subscription revenue.
Value-chain position
Arrow sits in the middle of two specialty value chains. In water-soluble films it buys PVA resin and additives and performs batching, casting, slitting, curing, embossing, printing and packing [IP-Aug26] — converting a commodity polymer into a performance film sold to formulators and packagers (agrochemical and detergent companies, embroidery converters). In security products it supplies engineered security elements into high-security paper mills and document/brand-protection converters, making it a Tier-2 supplier upstream of security printers. It describes itself as "part of the niche group supplying such products globally", with "100% indigenous technologies" [IP-Aug26].
Customers and end-markets
| End-market | Products | Customer type | Disclosure status |
|---|---|---|---|
| High-security paper (currency/cheque/passport-grade papers) | Security threads, multicolour fibres/planchettes, colour-shift films | Paper mills, security printers | Company says it is a "supplier to leading paper mills"; customer names not disclosed [IP-Aug26] |
| Document and brand protection | Security laminates, self-destructive security packaging film, labels | Brand owners, converters, document issuers | Customers not disclosed |
| Agrochemicals | Agrochemical packaging WSF | Agrochemical formulators (India, Brazil) | Q1 FY26 commentary noted increased exports to Brazil and negligible exports to the USA [ScanX] |
| Home & laundry care | Detergent (AD) film, toilet-block film, Watersol Capsules | FMCG / private-label | — |
| Textiles | Embroidery backing film | Embroidery units | — |
| Construction chemicals, dyes & pigments | Packaging film | Chemical companies | — |
| Healthcare | Water-soluble laundry bags for contaminated linen; MDS | Hospitals; pharma/nutraceutical brand owners (CDMO) | Avery states a long-term contract signed with a "big MNC company for export markets" (counterparty undisclosed) [IP-May26] |
Independent characterisation
Arrow Greentech is best understood as a small security-materials company with a green-packaging hedge rather than the reverse. On FY26 numbers, High-Tech produced ~82% of revenue and, given the margin profile (the consolidated EBITDA margin moves from ~25% to ~41% as High-Tech revenue swings, per Q4 FY26 vs Q1 FY27 [IP-May26; IP-Aug26]), an even larger share of profit. The segment's customer concentration, procurement-driven order timing and the Netherlands subsidiary's outsized contribution (Advance Secure Products B.V. turnover INR 396 Mn and PAT INR 78 Mn in FY26 [AR26 AOC-1]) imply limited earnings visibility. The Green segment is structurally attractive (plastic-substitution tailwinds, India leadership) but at INR 369 Mn is too small to anchor valuation. The patent estate is real and growing, but direct licensing income is not quantified, so the "IP moat" thesis is evidenced more by grants than by disclosed monetisation.
Strategy
Stated strategy (themes from FY26 Annual Report and investor materials)
The Chairman's FY26 letter sets out four explicit priorities for FY27 and beyond [AR26]:
-
Scale the Green Products business through new capacity (Dahej-II) and new applications, positioned against "a structural and irreversible global shift toward sustainable packaging".
-
Convert the IP pipeline into "the next generation of security solutions and related business verticals".
-
Grow Avery toward regulated markets through partnerships and approvals.
-
Expand the international footprint via the UK and Netherlands subsidiaries.
Cross-cutting themes: Make in India / Atma-Nirbhar Bharat alignment (import substitution in security materials and conservation of foreign exchange), a "fortress balance sheet", disciplined capital allocation, and continued R&D investment [AR26]. The FY26 results commentary added a High-Tech "recalibration" agenda to realign with evolving customer demand and geopolitical factors, plus cost discipline and mix shift to "higher-value, differentiated offerings" [IP-May26].
Initiative register (last 24 months)
| Initiative | Date | Description | Status / target | Source |
|---|---|---|---|---|
| Dahej-II Greentech capacity | Land Sept 2023; ongoing | ~3-acre GIDC plot for WSF/green expansion; phase 1 targeted in ~18 months | Not confirmed complete as of FY26 AR; capex spend low | BSE 15 Sep 2023; [AR26] |
| ESOP Scheme 2024 | Approved 16 Sep 2024 | Up to 225,000 options to attract/retain talent | Grants not disclosed | [AR26] |
| Patent expansion programme | 2025–2026 | Grants in US, Europe, India, Sri Lanka, Malaysia, Singapore for colour-shift films, security laminates, fibres, graphene thread | 24 in-force patents (May 2026); 10+ Indian and 3 foreign applications pending | [IP-May26]; exchange filings |
| Avery regulated-market push | 2025–2026 | Product registrations in Russia, Yemen, Vietnam; CDMO projects; long-term MNC export contract | Revenue INR 37 Mn FY26; loss continuing | [IP-May26]; [AR26] |
| High-Tech recalibration | From Q4 FY26 | Re-engagement with customers, mix shift, procurement participation | Q1 FY27 High-Tech revenue +137% YoY | [IP-May26]; [IP-Aug26] |
| Green export diversification | FY26 | Increased exports to Brazil; US de-emphasised | Forex earnings +118% FY26 | [ScanX]; [AR26] |
| Investor outreach | 2025–2026 | Regular quarterly presentations; MUFG Intime as IR adviser; analyst meets (e.g. 15 Jun 2026) | Ongoing | ScanX; [IP-Aug26] |
| Auditor rotation | Sept 2026 | KNAV & Co. LLP replaces Haribhakti & Co. LLP | Effective FY27 | [AR26] |
ESG commitments
No quantified emissions, energy or circularity targets were identified. The company's environmental positioning rests on its product portfolio (PVA water-soluble and compostable films displacing conventional plastics) and FIPSA 2026 recognition [AR26].
Guidance and medium-term targets
Management does not provide quantitative revenue, margin or capex guidance. Q1 FY27 commentary expresses "confidence" for the balance of FY27 without numbers [IP-Aug26]. No medium-term financial targets disclosed.
Products & Services
Green Products — Watersol® water-soluble films (WSF)
| Product | Description / application | Target customer | Notes |
|---|---|---|---|
| AD Film (detergent packaging film) | Unit-dose pouches for powder/liquid detergents, dishwash | FMCG, private label | Flagship consumer-goods application |
| Agrochemical packaging film | Pre-measured pesticide/fertiliser packs reducing handler exposure | Agrochemical formulators | Exports to Brazil increased in Q1 FY26 [ScanX] |
| Dyes & pigments packaging film | Dust-free dosing of dyes/pigments | Chemical/dye houses | — |
| Construction chemical & fibre packaging | Dissolvable packs for admixtures/fibres added to concrete | Construction-chemical companies | — |
| Toilet-block packaging film | Wrapping for toilet blocks | Home-care | — |
| Water-soluble laundry bag | PVOH bags for hygienic handling of contaminated hospital linen | Hospitals, healthcare laundries | — |
| Mould-release film | Release film in moulding | Composites/industrial | — |
| Embroidery film | Water-soluble backing removed after embroidery | Textile/embroidery units | — |
| Seed bomb / seed tape packaging | Dissolvable seed carriers | Horticulture | — |
| Cold Water Soluble Film | Patented variant (India grant 20 Feb 2024) | Packaging | [IP-May26] |
| Improved Water Soluble Film | Patented (India grant 12 Dec 2023) | Packaging | [IP-May26] |
| Edible water-soluble packaging film | Patented (India grant 5 Jun 2012) | Food | [IP-May26] |
| Historic variants | Water-transfer printing film, soap film ("Arrow Magic Strips"), fish-bait film, enzyme film, battery separator, dust-protection film | Various | Listed in 2019–2023 presentations; current commercial status not confirmed |
The core technology is a flexible PVA/PVOH film that dissolves fully in water without residue; capability claims include tensile strength to handle 10 g–10 kg loads, moisture/heat sealing, accurate dosing, optimum tear and puncture resistance, organic-solvent resistance, machine-automation compatibility, anti-static and odourless properties [IP-Aug26]. Pricing: not publicly disclosed.
Green Products — other
| Product | Description | Status |
|---|---|---|
| BioPlast (bio-compostable film) | Compostable alternative to single-use plastic; supported by Indian patent "Bio-Compostable Multi-Layered Composite" (grant 10 Jan 2024) | Commercial; revenue not separately disclosed [IP-Aug26; BSE filing 6 Feb 2024] |
| Watersol Capsules (formerly marketed as KlenzPro) | Highly concentrated hygiene/cleaning products in water-soluble capsules, no plastic waste | Commercial; scale not disclosed [IP-Aug26; Nov 2023 presentation] |
High-Tech Products — security and anti-counterfeit
| Product / technology | Description | Protection | Target customer |
|---|---|---|---|
| Security threads for high-security paper | Anti-counterfeit threads embedded in security papers (cheques, banknote-grade, passport papers) | Process know-how; "Security Yarn" patent (India, 8 Sep 2023) | Security paper mills |
| Multicolour security fibres / planchettes | Coloured fibres/planchettes embedded in high-security paper | Indian Patent No. 580835 (granted 17 Feb 2026) | Paper mills |
| Colour Shift Base Film | Base film exhibiting colour shift | Indian Patent No. 589622 (granted 2026; term from 18 Mar 2021) | Security printers, film converters |
| Dual-Colour Shift Security Film | Document security via dual colour-shift effect | US Pat. 12194771 (14 Jan 2025); Europe (30 Apr 2026); India (announced 12 Aug 2026) | Document issuers, security printers |
| Graphene-based security thread | Next-generation thread | India grant (20 Jun 2026 per [IP-Aug26]) | Paper mills |
| Security laminates to secure documents | Laminates incorporating security elements | UK (24 Jan 2024), Sri Lanka (5 Jun 2025), Malaysia MY-211221-A (19 Nov 2025), Singapore 11202252919H (31 Aug 2026) | ID/document issuers |
| Self-destructive irreversible security packaging film | Tamper-evident packaging | US (23 Aug 2016; divisional 7 Dec 2021) | Brand owners |
| High-security film (method and product) | Security film manufacturing process | Europe (15 Aug 2012) | Converters |
| High-strength paper | Paper and process | US (22 Nov 2011); Europe (5 May 2010) | Paper/packaging |
| Raw-material supply | Trading of raw materials to security customers | — | Paper mills/converters |
Intellectual-property services
Out-licensing, know-how transfer and technology partnerships managed by the Mumbai IP cell [AR26; IP-Aug26]. Licensees, royalty rates and IP revenue: not publicly disclosed.
Printing and self-adhesive (PSA) materials (patent-backed)
| Technology | Grant | Application |
|---|---|---|
| New improved self-adhesive materials with water-soluble films | India, 30 Oct 2023 | Labels |
| Self-adhesive materials with water-soluble protective layer | US, 9 Nov 2010 | Labels |
| Self-adhesive wallpaper with reduced adhesive and WSF | India, 16 Mar 2023 | Wallcoverings, hoardings |
Health & hygiene technologies (patent-backed)
| Technology | Grant | Application |
|---|---|---|
| Medicated bands | India, 13 May 2024 | Healthcare |
| WSF-based matrix to contain samples from living species | Europe 24 Jul 2013; USA 18 Mar 2014 | Bio-sample collection/disposal ("RX Matrix") |
| Cleaning device with sustained release of actives | India, 1 Feb 2023 | Hygiene |
| Active-embedded water-soluble film | Granted (jurisdiction per Avery materials) | Basis of MDS platform |
Avery Pharmaceuticals — Arrow RX mouth-dissolving strips (MDS)
| Category | Named products (selection, verbatim from company lists) |
|---|---|
| Nutraceutical MDS (FSSAI) | Vitamin B12; Vitamin D3; D3+K2; D3+K2+Calcium; Folic Acid; L-Methyl Folate; B-Complex; B3; Vitamin C; C+Zinc; C+Zinc+D3; K2; Iron; Zinc Picolinate; Lactoferrin; Ashwagandha; Curcumin; Curcumin+Piperine; Astaxanthin; Lutein+Zeaxanthin; Clove Oil; Hemp; Echinacea+Propolis; L-Arginine+Caffeine; Caffeine combinations; Melatonin (incl. "Sleep MX" brand) and combinations; Millet+Vitamins; Bacillus Coagulans+FOS; Probiotics; Immune Booster; Multivitamin complex; mouth-freshener films; food-grade edible film; Hangover MDS |
| Rx — WHO-GMP products | Nicotine Polacrilex MDS (1/2/4 mg); Ondansetron MDS (4/8 mg); Sildenafil MDS (25/50 mg) |
| Rx — licensed for domestic & export | Amlodipine MDS; Tadalafil ODS; Vitamin D3 MDS (2,000/60,000 IU); Vitamin B12 MDS; "NOS Primes Spiced Rose" 2 mg |
| Rx — test licence (pipeline) | Clonazepam, Dextromethorphan, Donepezil, Eliglustat sublingual film, Ketorolac, Levocetirizine, Levocetirizine+Montelukast, Montelukast, Paracetamol, Rizatriptan, Simethicone, Voglibose, Zolmitriptan ODS |
| Platforms | MDS films (NDDS), Novel Drug Delivery Device (controlled release), RX Matrix (bio-sample collection) |
Facility: WHO-GMP, FSSAI, GLP, ISO 9001 and ISO 22000 certified plant with in-house product development centre at Sanand, Gujarat. Portfolio: 54+ FSSAI-approved nutraceutical products and 10+ Rx-approved products; registrations being pursued in Russia, Yemen and Vietnam; CDMO projects; long-term export supply contract with an unnamed MNC [IP-May26; IP-Aug26].
Commercial scale: Avery turnover INR 37.0 Mn in FY26 (FY25: INR 18.1 Mn) with losses of INR 36.1 Mn (FY25: INR 47.4 Mn) [AR26 AOC-1]. Pricing: not disclosed.
Financial Narrative
Income statement: notes and sources
Sources: Revenue, EBITDA, PAT from [IP-May26] five-year chart; gross profit FY22–FY24 from [SA], FY25–FY26 from [IP-May26] (FY25 gross profit shown as INR 1,304 Mn by [SA] vs INR 1,313 Mn by the company — discrepancy noted; company figure used); operating income from [SA]; other income approximated from [SCR] in crore for FY22–FY24 and [IP-May26] for FY25–FY26; EPS from [AR26] (Screener shows FY23 consolidated EPS INR 8.14 vs AR INR 8.52 — discrepancy noted); DPS from [AR26], [PR-Q4FY25], Upstox corporate actions. Diluted EPS: not separately disclosed in reviewed materials (no dilutive instruments outstanding identified other than ESOP 2024 authorisation; diluted ≈ basic).
Margins and growth (consolidated)
Revenue CAGR FY22–FY26 (4-year): ~56% (base effect from trough FY22). Revenue CAGR FY23–FY26 (3-year): ~22.6%. Five-year sales CAGR per Screener (FY21 base): 31% consolidated [SCR]. PAT margins as presented by the company on revenue from operations are -26%/11%/19%/25%/23% (FY22–FY26), slightly different from the computed figures above due to the treatment of PAT attributable vs total [IP-May26].
Quarterly P&L — last five quarters
Sources: [IP-Aug26], [IP-May26], [IP-Jun25]; Q2 FY26 derived as FY26 total minus Q1, Q3, Q4; Q2 EPS from [SCR]. Trailing-twelve-month (Q2 FY26–Q1 FY27): revenue ~INR 2,468 Mn, EBITDA ~INR 862 Mn, PAT ~INR 639 Mn (≈ Screener TTM INR 247 Cr revenue / INR 63.9 Cr profit).
Q1 FY27 deep-dive. Revenue rose 110% QoQ and 111% YoY to INR 878 Mn; gross margin held at 54.7% (vs 55.5% in Q4 FY26), so the EBITDA margin expansion to 40.9% came from operating leverage — employee expense was flat at INR 47 Mn and other expenses fell to INR 75 Mn [IP-Aug26]. Management called it "a defining quarter" reflecting "commercial conversion of several years of investment" [IP-Aug26]. This single quarter delivered 58% of FY26's full-year PAT.
Balance sheet (consolidated)
Sources: FY25–FY26 from [IP-May26] consolidated balance sheet; FY22–FY24 totals, equity and borrowings from [SCR] (crore × 10); FY24 opening cash INR 76 Mn from [IP-May26] cash-flow statement. Zero values for FY22–FY24 in line-items denote not disclosed in the materials reviewed, not actual zeros. Zerodha reports net debt of INR -45.8 Cr (Mar-25) and INR -53 Cr (Mar-26), apparently counting only cash and bank balances — a definitional discrepancy versus the INR -127 Cr computed here including current investments.
Commentary. The balance sheet is the company's strongest feature. Equity more than tripled from ~INR 750 Mn (FY22) to INR 2,362 Mn (FY26), driven entirely by retained earnings; no equity has been issued since the March 2020 rights issue [AR26]. At March 2026, liquid assets of ~INR 1,294 Mn represented 51% of total assets and ~55% of equity. Current ratio rose from 10.3x (FY25) to 13.7x (FY26). The flip side is capital efficiency: a growing cash pile dilutes ROE (from ~40% in FY25 to ~22% in FY26) and has not yet been deployed into the Dahej expansion at scale.
Cash flow (consolidated)
Sources: FY25–FY26 from [IP-May26]; FY22–FY24 and FCF/capex from [SCR] (rounded crore). Dividends paid derived: FY24 pays FY23 DPS ~INR 1, FY25 pays FY24 INR 2, FY26 pays FY25 INR 4 (× 15.09 Mn shares). No buyback has been undertaken in the audit period [AR26 Secretarial Audit].
Commentary. Cash conversion has improved sharply: CFO/EBITDA was ~103% in FY25 and ~94% in FY26 (Screener basis) versus 25% in FY23 [SCR]. FY26 CFO fell to INR 431 Mn as working capital absorbed INR 94 Mn (inventories +INR 51 Mn, receivables +INR 49 Mn) [IP-May26]. Investing outflows are dominated by treasury deployment into current investments rather than capex; capex has run at only INR 40–100 Mn a year, which is inconsistent with a meaningful Dahej build-out to date.
Ratio analysis
Sources: ROE/ROCE from [IP-May26] five-year chart (decoded as ROE -12/14/26/40/22 and ROCE -12/21/36/54/31, consistent with Screener ROCE of -12/21/35/53/30); other ratios computed by analyst from figures above; CCC/debtor/inventory days from [SCR]. ROIC is an analyst derivation (EBIT ex-OI × (1 − 27% tax) ÷ (total equity − net cash)) and should be treated as indicative. Zero placeholders mean not computed due to missing inputs.
Trend commentary. Three inflections stand out. (1) FY23 turnaround: the business moved from an EBITDA loss to a 22% margin on a tripling of revenue, consistent with the High-Tech segment's ramp. (2) FY25 peak: operating leverage took EBITDA margin to 36% and ROCE to 54%. (3) FY26 normalisation: revenue fell 18% but gross margin actually improved (54.5% vs 54.0%), showing the decline was volume/mix-driven at the High-Tech level rather than price erosion; EBITDA margin contracted 410 bps on fixed-cost deleverage. The working-capital cycle is structurally long (100+ days in most years), reflecting inventory-heavy specialty manufacturing and order-based billing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | AGL stake | Role | FY26 turnover (INR Lakh) | FY26 PAT (INR Lakh) | Source |
|---|---|---|---|---|---|---|
Arrow Greentech Ltd (parent) | India | — | WSF manufacturing (Ankleshwar), security products, IP cell | 16,470 (standalone total income) | 4,249 | [AR26] |
Arrow Green Technologies (UK) Ltd | UK | 100% | International holding/business development | 318 | 177 | [AR26 AOC-1] |
Advance IP Technologies Ltd | UK | 95% (via UK sub) | IP / technology | 336 | 34 | [AR26 AOC-1] |
Advance Secure Products B.V. | Netherlands | 100% (via UK sub) | Security products trading/supply into Europe | 3,962 | 778 | [AR26 AOC-1] |
Avery Pharmaceuticals Pvt Ltd | India | 99.65% (described as WOS) | Mouth-dissolving strips, CDMO (Sanand) | 370 | (361) | [AR26 AOC-1] |
LQ Arrow Security Products (India) Pvt Ltd | India | 51% | Security products JV | 58 | 8 | [AR26 AOC-1] |
Arrow Secure Technology Pvt Ltd | India | 100% | Effectively dormant (nil turnover) | 0 | (0) | [AR26 AOC-1] |
SP Arrow Bio Polymer Products Pvt Ltd | India | 46% (associate) | Bio-polymer; not consolidated (no control) | — | (0) | [AR26 AOC-1] |
Sphere Bio Polymer Pvt Ltd | India | Former associate | Strike-off applied 26 Mar 2025 | — | — | [AR25 AOC-1 as reproduced in AR26] |
Segment Overview
| Segment | Contents (per filings) | Key products |
|---|---|---|
Hightech Products | Anti-counterfeit products, IPRs, other high-tech products | Security threads, multicolour security fibres/planchettes, colour-shift and dual-colour-shift security films, security laminates, self-destructive security packaging film, graphene-based security thread, brand-protection elements, patent licensing |
Green Products | Water-soluble films, bio-compostable products, other green products | Watersol® WSF range, BioPlast compostable film, Watersol Capsules |
Revenue by Segment and Revenue by Segment (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hightech Products revenue (INR Mn; FY24 derived) | 1,224 | 2,191 | 1,636 |
Green Products revenue (INR Mn; FY24 derived) | 261 | 243 | 369 |
Total revenue from operations (INR Mn) | 1,485 | 2,434 | 2,005 |
Hightech share of revenue (%) | 82.4 | 90.0 | 81.6 |
Green share of revenue (%) | 17.6 | 10.0 | 18.4 |
Hightech YoY growth (%) | 0 | 79 | -25.3 |
Green YoY growth (%) | 0 | -6.9 | 51.9 |
Revenue by Segment
| Segment | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Hightech Products revenue (INR Mn; Q2 derived) | 344 | 488 | 458 | 346 | 816 |
Green Products revenue (INR Mn) | 72 | 123 | 103 | 71 | 63 |
Total revenue from operations (INR Mn) | 416 | 611 | 561 | 418 | 878 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Mn) | 337 | 1,088 | 1,485 | 2,434 | 2,005 |
Revenue growth YoY (%) | -35.7 | 223.1 | 36.5 | 63.9 | -17.6 |
Gross profit (INR Mn) | 137 | 539 | 890 | 1,313 | 1,093 |
EBITDA (INR Mn, company-defined, excl. other income) | -73 | 235 | 463 | 884 | 646 |
Operating income / EBIT excl. other income (INR Mn) | -100 | 188 | 394 | 817 | 568 |
Other income (INR Mn) | 20 | 20 | 30 | 53 | 85 |
Finance cost (INR Mn) | 6 | 8 | 2 | 2 | 4 |
Pre-tax income (INR Mn) | -110 | 180 | 407 | 860 | 650 |
Net income / PAT (INR Mn) | -93 | 123 | 293 | 630 | 474 |
EPS basic (INR) | -6.62 | 8.52 | 19.56 | 41.83 | 31.38 |
Dividend per share (INR; FY23 derived from ~12% payout) | 0 | 1 | 2 | 4 | 5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 40.7 | 49.5 | 59.9 | 54.0 | 54.5 |
EBITDA margin (%) | -21.7 | 21.6 | 31.2 | 36.3 | 32.2 |
Operating (EBIT ex-OI) margin (%) | -29.6 | 17.3 | 26.6 | 33.6 | 28.3 |
PAT margin (%) | -27.6 | 11.3 | 19.7 | 25.9 | 23.6 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations (INR Mn) | 416 | 611 | 561 | 418 | 878 |
Gross profit (INR Mn; Q2 not disclosed, shown as 0) | 237 | 0 | 304 | 232 | 480 |
EBITDA (INR Mn; Q2 derived) | 143 | 207 | 192 | 104 | 359 |
EBITDA margin (%) | 34.3 | 33.9 | 34.3 | 24.8 | 40.9 |
PBT (INR Mn; Q2 derived) | 143 | 208 | 193 | 106 | 363 |
PAT (INR Mn; Q2 derived) | 109 | 158 | 133 | 74 | 274 |
EPS (INR) | 7.21 | 10.43 | 8.81 | 4.90 | 18.15 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Mn) | 890 | 1,210 | 1,450 | 2,084 | 2,558 |
Total equity incl. NCI (INR Mn; FY22–FY24 from Screener crore) | 750 | 980 | 1,270 | 1,900 | 2,362 |
Borrowings (INR Mn; FY25–FY26 = lease liabilities) | 50 | 30 | 10 | 7 | 23 |
Cash & cash equivalents (INR Mn) | 0 | 0 | 76 | 167 | 268 |
Other bank balances (INR Mn) | 0 | 0 | 0 | 291 | 262 |
Current investments (INR Mn) | 0 | 0 | 0 | 454 | 764 |
Gross cash & liquid investments (INR Mn) | 0 | 0 | 0 | 912 | 1,294 |
Net debt (INR Mn; negative = net cash; Zerodha figures for FY25/FY26 basis differ) | 0 | 0 | 0 | -905 | -1,271 |
Goodwill & intangibles incl. under development (INR Mn) | 0 | 0 | 0 | 26 | 21 |
Inventories (INR Mn) | 0 | 0 | 0 | 202 | 253 |
Trade receivables (INR Mn) | 0 | 0 | 0 | 293 | 342 |
Net working capital incl. cash (INR Mn) | 0 | 0 | 0 | 1,378 | 1,842 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Mn; FY22–FY24 from Screener crore) | 20 | 30 | 180 | 676 | 431 |
Capex (INR Mn; derived CFO minus FCF from Screener) | 80 | 40 | 100 | 70 | 40 |
Free cash flow (INR Mn) | -60 | -10 | 80 | 610 | 390 |
Investing cash flow (INR Mn) | -20 | -140 | -140 | -546 | -259 |
Financing cash flow (INR Mn) | -20 | 80 | -40 | -39 | -71 |
Dividends paid (INR Mn; derived from prior-year DPS × shares) | 0 | 0 | 15 | 30 | 60 |
Buybacks (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, company-reported) | -12 | 14 | 26 | 40 | 22 |
ROCE (%, company-reported) | -12 | 21 | 36 | 54 | 31 |
ROA (%, PAT / average total assets) | -10 | 12 | 22 | 36 | 20 |
ROIC (%, derived NOPAT / equity less net cash; FY25–FY26 only) | 0 | 0 | 0 | 61 | 39 |
Current ratio (x; FY25–FY26 only) | 0 | 0 | 0 | 10.3 | 13.7 |
Debt to equity (x) | 0.07 | 0.03 | 0.01 | 0.00 | 0.01 |
Net debt to EBITDA (x; FY25–FY26) | 0 | 0 | 0 | -1.0 | -2.0 |
Interest coverage (EBIT incl. OI / finance cost, x) | -15 | 26 | 212 | 431 | 163 |
Asset turnover (x, revenue / average assets) | 0.36 | 1.04 | 1.12 | 1.37 | 0.86 |
Cash conversion cycle (days, Screener consolidated) | 106 | 121 | 187 | 81 | 141 |
Debtor days (Screener consolidated) | 40 | 88 | 79 | 44 | 62 |
Inventory days (Screener consolidated) | 127 | 101 | 138 | 66 | 101 |
Revenue by Region
| Metric | FY2025 | FY2026 |
|---|---|---|
Standalone foreign-exchange earnings (INR Mn) | 61.0 | 133.1 |
Standalone foreign-exchange outgo (INR Mn) | 146.1 | 180.9 |
Advance Secure Products B.V. (Netherlands) turnover (INR Mn) | 363.3 | 396.2 |
Arrow Green Technologies (UK) turnover (INR Mn) | 51.3 | 31.8 |
Advance IP Technologies (UK) turnover (INR Mn) | 0 | 33.6 |
Consolidated minus standalone revenue from operations (INR Mn) | 374 | 358 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Price (19 Oct 2026, intraday) | INR 776 | [SCR] |
Price (16 Oct 2026, close) | INR 806 | [SCR] |
52-week high / low | INR 953 / INR 342 | [SCR] |
Lifetime high / low | INR 1,099 / INR 30.30 | Anand Rathi |
1-year return | +46% | [SCR] |
YTD 2026 (to 8 Oct 2026) | +67.6% | MarketScreener |
3-year price CAGR | 23% | [SCR] |
5-year price CAGR | 46–48% | [SCR] |
10-year price CAGR | 7% | [SCR] |
Metric | 2,024 | 2,025 |
Representative share price (INR; 21 Nov 2024, 13 Jun 2025, 16 Oct 2026) | 907 | 607 |
Valuation Multiples
| Multiple | Arrow Greentech | Peers |
|---|---|---|
Market cap (INR Cr) | ~1,171 | Indian film peer median market cap ~INR 3,003 Cr (Zerodha) |
Enterprise value (INR Cr) | ~1,044 (mkt cap − INR 129 Cr liquid assets + INR 2 Cr leases) | — |
P/E (TTM, EPS INR 42.30) | ~18.3x (Screener shows 19.0–19.7x) | Value Research peer median 18.7x (Jun 2026) |
EV/EBITDA (TTM EBITDA ~INR 86 Cr) | ~12.1x | — |
EV/Sales (TTM revenue ~INR 247 Cr) | ~4.2x | — |
P/B (book value INR 155) | ~5.0x | Value Research peer median 1.3x (Jun 2026) |
Dividend yield (INR 5) | ~0.64% | — |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
DPS (INR; FY23 derived) | 0 | 1 | 2 | 4 | 5 |
Consolidated payout (%) | 0 | 12 | 10 | 10 | 16 |
Capital Markets
| Item | Status |
|---|---|
Buyback authorisations | None during audit period [AR26] |
Equity issuance | None since March 2020 rights issue; ESOP 2024 authorised (225,000 options) |
Debt maturity profile | Not applicable — no borrowings other than INR 23 Mn lease liabilities (INR 7 Mn current, INR 16 Mn non-current) at 31 Mar 2026 [IP-May26] |
Analyst consensus | No sell-side coverage or consensus estimates identified |
Analyst Conclusions
Management guidance
No quantitative guidance. Management expresses confidence for the remainder of FY27 following Q1, prioritising product-portfolio development and sustainable innovations [IP-Aug26], and lists four strategic priorities (Green capacity, IP conversion, Avery regulated markets, international expansion) [AR26].
Consensus expectations
No published consensus. Screener's automated flag that the company "is expected to give good quarter" is a machine-generated signal, not an estimate [SCR].
Bull case
-
Earnings power re-established: Q1 FY27 PAT of INR 274 Mn alone is 58% of FY26 PAT; even modest follow-through could put FY27 PAT above the FY25 record of INR 630 Mn.
-
Cash-adjusted valuation is undemanding: with ~11% of market cap in liquid assets, the core business trades at ~12x TTM EV/EBITDA despite 30–40% EBITDA margins and a 24-patent estate.
-
Green optionality: a segment that grew 52% in FY26 in a 5.8%-CAGR global market, with export momentum (forex earnings +118%) and a land bank for expansion.
Bear case
-
Lumpiness is structural: FY26 showed High-Tech can fall 25% with little warning; one strong quarter does not establish a run-rate, and no customer concentration data is provided.
-
Governance and capital allocation: material RPT with a promoter-family firm at ~21% of revenue in value, a 30% promoter pay rise after a down year, and a 16% payout despite surplus cash.
-
Execution drag: Dahej-II capacity appears behind its original 18-month target; Avery continues to lose money; capex of only INR 40 Mn in FY26 is inconsistent with a scale-up narrative.
Catalysts and monitorables (next 12 months)
| Item | Expected timing | What to watch |
|---|---|---|
| Q2 FY27 results | ~Nov 2026 (trading window closed 30 Sep) | Sustainability of High-Tech run-rate above INR 500 Mn/quarter; Green recovery |
| Q3 FY27 results | ~Feb 2027 | Working-capital normalisation (CCC <120 days) |
| Dahej-II commissioning | Unconfirmed | Capex step-up in cash flow; capacity disclosure |
| Avery breakeven | FY27–FY28 | Revenue from MNC export contract; regulated-market approvals |
| Patent licensing | Ongoing | First quantified IP/licensing revenue disclosure |
| Capital allocation | FY27 | Use of ~INR 1.3 Bn cash: capex, dividend increase, buyback |
| RPT trajectory | 35th AGM (2027) | ABS purchase values vs INR 70 Cr limit |
| Institutional ownership | Quarterly | DII creep (1.02% Sep 2026) |
| Auditor transition | FY27 audit by KNAV | Any changes in accounting presentation |
Analyst verdict
Arrow Greentech is a genuinely differentiated small-cap: an Indian company with a three-decade record of inventing and patenting functional films, a defensible domestic leadership in water-soluble PVA films, and a security-materials franchise that, when orders flow, produces margins most Indian specialty-chemical and packaging companies cannot match. The balance sheet is pristine — about INR 1.3 billion of liquidity, negligible debt, equity built entirely from retained earnings since 2020 — and cash conversion has improved materially since FY24.
The investment problem is predictability, not quality. Four-fifths of revenue comes from a High-Tech segment whose customers, contract structures and margins are not disclosed, and whose output swung from a 25% annual decline in FY26 to a 137% quarterly increase in Q1 FY27. A significant share of the international business runs through a Netherlands subsidiary that receives minimal narrative disclosure. The Green segment, while growing well, remains below a fifth of revenue and its capacity expansion appears delayed. Avery is an interesting technology platform but, at INR 37 million of revenue and continuing losses, is not yet a value driver.
Governance is acceptable but warrants monitoring: the company meets independence requirements and receives clean audit and secretarial reports, yet the material related-party supply arrangement with a promoter-family partnership, the combined Chair/MD role and a 30% pay rise for promoter-executives in a down year are legitimate minority-shareholder concerns. The September 2026 auditor rotation to KNAV is a neutral-to-positive procedural event.
At ~18x trailing earnings and ~12x EV/EBITDA, the stock prices in partial durability of the Q1 FY27 step-up. We would characterise it as a high-volatility, IP-rich, cash-rich special situation.
APPENDIX — SOURCES
[AR26]: Arrow Greentech Annual Report FY2025-26 incl. 34th AGM Notice (NSE filing, 26 Aug 2026) — https://nsearchives.nseindia.com/corporate/ARROWGREEN_26082026195520_AnnualReport26082026.pdf
[IP-Aug26]: Investor Presentation — Q1 FY27 (Aug 2026) — https://www.arrowgreentech.com/images/presentation/2026-27/AGTL%20Presentation%20Aug%202026.pdf
[IP-May26]: Investor Presentation — Q4 & FY26 (25 May 2026) — https://nsearchives.nseindia.com/corporate/ARROWGREEN_25052026134259_PresentationOnBusinessPerformanceOfTheCoMay2026.pdf
[IP-Jun25]: Investor Presentation — Q1 FY26 — https://www.arrowgreentech.com/images/presentation/2025-26/AGTL%20Investor%20Presentation%20Jun%202025.pdf
[PR-Q4FY25]: Press Release Q4/FY25 (17 May 2025) — https://nsearchives.nseindia.com/corporate/ARROWGREEN_17052025182428_Arrow_Greentech_Press_Release-Q4FY25.pdf
[PR-Q3FY26]: Press Release / Presentation Q3 FY26 (13 Feb 2026) — https://bsmedia.business-standard.com/_media/bs/data/announcements/bse/15022026/42220f68-9210-4374-bdb1-80d5931af8b6.pdf
[SCR]: Screener.in — consolidated and standalone financials, shareholding, announcements — https://www.screener.in/company/ARROWGREEN/consolidated/
[SA]: StockAnalysis.com income statement — https://stockanalysis.com/quote/nse/ARROWGREEN/financials/
BSE-Dahej: GIDC Dahej-II plot transfer intimation (15 Sep 2023) — https://bseindia.com/xml-data/corpfiling/AttachHis/339db135-7c94-4c22-b130-4c0ac36ea49a.pdf
BSE-Rights: Rights issue filings (3 Feb 2020; 19 Mar 2020) — https://bseindia.com/xml-data/corpfiling/AttachHis/03be1e47-1c5b-4734-94bb-cff29d1d1501.pdf
Patent filings: Malaysia (17 Feb 2026); India 580835 (23 Feb 2026); Sri Lanka (30 Jan 2026); bio-compostable (6 Feb 2024) — https://nsearchives.nseindia.com/corporate/ARROWGREEN_17022026123213_GrantOfPatent17022026.pdf ; https://nsearchives.nseindia.com/corporate/ARROWGREEN_23022026140835_GrantOfPatent23022026.pdf
Sahi: Singapore patent and Colour Shift Base Film coverage — https://www.sahi.com/news/arrow-greentech-granted-singapore-patent-for-secure-laminates-to-secure-documents
LegalSuvidha: Patent updates Jul/Aug 2026 — https://legalsuvidha.com/latest-updates/arrow-greentech-granted-patent-070726
ScanX: Q1/Q2 FY26 results, analyst meet, patent news — https://scanx.trade/stock-news/arrow-greentech-ltd
Multibagg: FY26 and Q1 FY27 analyses — https://www.multibagg.ai/market-pulse/articles/arrow-fy26-94908
Univest: Q1 FY27 results and price reaction — https://univest.in/blogs/arrow-greentech-q1-results-fy27-pat-27-crore
MarketScreener: Event calendar and price — https://www.marketscreener.com/quote/stock/ARROW-GREENTECH-LIMITED-23640775/calendar/
Morningstar: Business description; employees — https://morningstar.com.au/investments/security/NSE/ARROWGREEN
Zerodha: Peer set; net debt; dividends — https://zerodha.com/markets/stocks/BSE/ARROWGREEN/
Value Research: Peer multiples; 52-week range — https://www.valueresearchonline.com/stocks/41106/arrow-greentech-ltd/
Company history: IIFL, Arihant, Goodreturns, Sharekhan profiles — https://www.indiainfoline.com/company/arrow-greentech-ltd/summary ; https://www.goodreturns.in/company/arrow-greentech/history.html
FilingReader: FY25 and FY26 annual-report summaries — https://filingreader.com/news-wire/mumbai/2026-08-26/arrow-greentech-reports-inr-2005m-revenue-for-fy26
Derived figures are labelled as such.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Age | Board tenure | Education | Background | Shares held (31 Mar 2026) |
|---|---|---|---|---|---|---|
Shilpan P. Patel | Chairman & Managing Director (KMP, promoter) | 70 | Since 30 Oct 1992; current term 1 Apr 2025 – 31 Mar 2030 (special resolution passed for continuation past age 70) | MBA, Sam Houston State University (Texas); B.Com, H.L. College of Commerce, Ahmedabad | ~9 years at Grace Paper Industries; inventor of Arrow's WSF (1990); leads business development, strategy and IP cell; named inventor on patents in USA, Europe, South Africa, Australia, India | 52,39,557 (~34.7%) |
Neil S. Patel | Joint Managing Director (KMP, promoter group) | 40 | Additional Director 1 Jun 2012; with company since 2009; current term from 1 Apr 2025 | M.Sc. Biomedical Science, Kingston College, London | Operations leadership; Audit and Stakeholders' Relationship Committee member; director of Avery, UK subsidiaries | 4,10,272 (~2.7%) |
Jigisha S. Patel | Non-Executive, Non-Independent Woman Director (promoter group; wife of CMD) | 69 | Since 14 Jul 2020 | B.A., Calcutta | Administration; partner in related party Advance Business Solutions | 16,97,205 (~11.2%) |
Prashant S. Mehta | Independent Director; Chair of Audit and NRC | 72 | Since 13 Feb 2024 | B.Com (Narsee Monjee, 1976); LLB (New Law College, 1978); Company Secretary | 40+ years legal/secretarial at Premier Ltd, JISCO (now JSW Steel), Shoppers Stop | — |
Yogesh Gajjar | Independent Director; Chair of Stakeholders' Relationship Committee | 73 | Since 8 Feb 2025 | Diploma in Electronics (Govt Polytechnic, 1975) | 45 years in electricals/electronics services business, Ahmedabad | — |
Barkharani H. Nevatia | Independent Woman Director | 32 | Since 13 Feb 2024 | Chartered Accountant; LLB (Mumbai University); Narsee Monjee College | Practising CA (Pune/Mumbai): corporate tax, statutory audit, GST, income tax | — |
Hitesh Punglia | Chief Financial Officer (KMP) | — | — | — | — | — |
Poonam Bansal | Company Secretary & Compliance Officer (KMP) | — | At least since 2020 (signed Jan 2020 rights filings) | — | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Executive | FY26 salary basis | Revised (w.e.f. 1 Jul 2026) | Other | Source |
|---|---|---|---|---|
Shilpan P. Patel (CMD) | INR 9.00 lakh/month (INR 1.08 Cr p.a.) + PF, gratuity, perquisites | INR 11.70 lakh/month (INR 1.404 Cr p.a.), +30% | Chauffeur-driven car, superannuation, reimbursements; capped within Section 197 limits (5% of net profit per executive director, 10% all EDs) | [AR26] Notice items 6 |
Neil S. Patel (JMD) | INR 9.00 lakh/month (INR 1.08 Cr p.a.) | INR 11.70 lakh/month (INR 1.404 Cr p.a.), +30% | Same structure | [AR26] Notice item 7 |
CFO, CS | Not disclosed in extracted text | — | — | — |
Directors' Remuneration by Attribute
| Attribute | Status |
|---|---|
Board size | 6 |
Independent directors | 3 of 6 (50%) — meets SEBI LODR requirement for a board chaired by an executive promoter |
Women directors | 2 (Jigisha Patel, Barkharani Nevatia) |
Chair/CEO separation | No — Shilpan Patel is both Chairman and MD |
Promoter family on board | 3 of 6 |
Audit Committee | Chair: Prashant Mehta; members: Yogesh Gajjar, Barkharani Nevatia, Neil Patel |
Nomination & Remuneration Committee | Chair: Prashant Mehta; members: Yogesh Gajjar, Barkharani Nevatia |
Stakeholders' Relationship Committee | Chair: Yogesh Gajjar; members: Neil Patel, Prashant Mehta |
FY26 meetings | 4 Board, 4 Audit Committee; separate Independent Directors' meeting 13 Feb 2026 |
Shareholding Trend
| Holder category | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|
Promoters (%) | 68.60 | 64.81 | 64.83 | 65.65 |
FIIs (%) | 1.28 | 0.27 | 0.06 | 0.08 |
DIIs (%) | 0.00 | 0.04 | 0.82 | 1.02 |
Public (%) | 30.13 | 34.88 | 34.28 | 33.26 |
Number of shareholders | 13,430 | 22,605 | 21,442 | 20,500 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | HQ | Listing / ownership | Relative positioning vs Arrow |
|---|---|---|---|---|
Water-soluble films | MonoSol (Kuraray Co.) | USA/Japan | Kuraray listed (Tokyo) | Global leader in PVOH films for unit-dose detergents; vastly larger scale and resin integration |
Water-soluble films | Mitsubishi Chemical Group (Hi-Selon PVOH film) | Japan | Listed (Tokyo) | Integrated PVOH resin and film producer |
Water-soluble films | Sekisui Chemical (PVOH films) | Japan | Listed (Tokyo) | PVOH specialty films/resins |
Water-soluble films | Aicello Corporation (Solublon) | Japan | — | Specialist WSF producer |
Water-soluble films | Chinese PVA film makers (e.g. Guangdong/Jiangmen-based producers) | China | Mostly private | Low-cost competition in commodity grades |
Security threads/features | SICPA | Switzerland | Private | Global leader in security inks/authentication |
Security threads/features | Crane NXT (Crane Currency) | USA | NYSE-listed | Leader in micro-optic security threads and banknote substrates |
Security films/holograms | Leonhard Kurz | Germany | Private | Hot-stamping foils, optical security features |
Security printing/features | Giesecke+Devrient | Germany | Private | Banknote and security features |
Brand protection/holography (India) | Holostik India | India | Private | Domestic anti-counterfeit labels and holograms |
Packaging films (Indian listed peers per Zerodha) | Uflex, Polyplex, Cosmo First, Jindal Poly Films, Xpro India, Nahar Poly Films | India | NSE/BSE listed | Commodity/specialty BOPET/BOPP film makers — size peers for valuation, not direct product competitors; Zerodha cites peer median market cap ~INR 3,003 Cr vs Arrow ~INR 1,091 Cr |
Peer Comparison FY2026
| Metric | Arrow Greentech (FY26) | Arrow Greentech (TTM to Q1 FY27) |
|---|---|---|
Revenue (INR Mn) | 2,005 | 2,468 |
Revenue growth (%) | -17.6 | 13 (Screener TTM) |
EBITDA margin (%) | 32.2 | ~35 |
PAT margin (%) | 23.6 | ~26 |
ROE (%) | 22 | 21 (Screener) |



